Angiogenesis inhibition in neurooncology

作者：Tabatabai G^*; Stupp R

来源：Nervenarzt, 2010, 81(8): 936-939.

DOI：10.1007/s00115-010-2957-0

• Neurooncology
• Angiogenesis inhibition
• Vascular endothelial growth factor
• Resistance mechanisms
• Phenotype

The application of angiogenesis inhibitors in neurooncology is increasing. Initially, these drugs seemed to be very promising because of the surprisingly high neuroradiological response rates that were observed in first clinical trials. Meanwhile, this enthusiasm is waning, as the high response rates did not translate into substantial improvements in progression-free and overall survival. Tumor progression during or after antiangiogenic therapy is often associated with rapid clinical neurological deterioration and sometimes even with diffuse infiltrative gliomatosis-like neuroradiological phenotypes. Thus, the characterization and understanding of escape mechanisms are needed. The identification of criteria for defining the personalized use of angiogenesis inhibitors remains a challenge.

• 出版日期2010-8